2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology/American Heart Association …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid
P Garcia-Pavia, F Aus dem Siepen… - … England Journal of …, 2023 - Mass Medical Soc
Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal
disease caused by misfolded transthyretin. Despite advances in slowing disease …
disease caused by misfolded transthyretin. Despite advances in slowing disease …
2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
E Arbelo, A Protonotarios, JR Gimeno… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
Authors/Task Force Members:… - European journal of …, 2022 - Wiley Online Library
Abstract Document Reviewers: Rudolf A. de Boer (CPG Review Coordinator)(Netherlands),
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
P. Christian Schulze (CPG Review Coordinator)(Germany), Magdy Abdelhamid (Egypt) …
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and …
The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
P Garcia-Pavia, C Rapezzi, Y Adler, M Arad… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
Patisiran treatment in patients with transthyretin cardiac amyloidosis
MS Maurer, P Kale, M Fontana, JL Berk… - … England Journal of …, 2023 - Mass Medical Soc
Background Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with
accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive …
accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive …
CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis
JD Gillmore, E Gane, J Taubel, J Kao… - … England Journal of …, 2021 - Mass Medical Soc
Background Transthyretin amyloidosis, also called ATTR amyloidosis, is a life-threatening
disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein …
disease characterized by progressive accumulation of misfolded transthyretin (TTR) protein …
[HTML][HTML] Gene therapy clinical trials, where do we go? An overview
There have been many ups and downs since the introduction of gene therapy as a
therapeutic modality for diseases. However, the journey of gene therapy has reached a …
therapeutic modality for diseases. However, the journey of gene therapy has reached a …